Drug Target Review

SEPTEMBER 22, 2023

5 Organoids are recognised as New Alternative Methods (NAMs) in drug development. This recognition was codified by the United States Food and Drug Administration (FDA) in 2022 with the signing of the FDA Modernisation Act 2.0 This can aid in the development of safer, more effective therapeutic strategies.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

DrugBank

MAY 15, 2024

This method was more about serendipity than science. But as molecular biology has advanced, so too has our approach to finding new drugs. Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Drug Target Review

MAY 27, 2024

Caris Life Sciences® (Caris) has been at the forefront of precision medicine. How does the company see antibody-drug conjugates (ADCs) fitting into this approach? However, biopharma pipelines have been focused on optimising linkers and payloads around a relatively small number of cell-surface targets.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

The Pharma Data

JANUARY 6, 2021

(“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. Südhof, M.D.,

Science 52

Science Molecular Biology Treatment Production 52

Alta Sciences

JUNE 11, 2024

via Wikimedia Commons My fellow Altascientists and I recently attended the 2024 annual Boston Society Gene & Cell Therapy Conference , held at the wonderful Museum of Science in, of course, Boston, MA. Connect with Dr. Turcotte on LinkedIn. Image Thumbnail_Blog_June 2024.jpg

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Elrig

APRIL 29, 2024

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. During this time, I had the opportunity to step in as an interim Discovery Sciences project lead, sparking my interest in project leadership.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Alta Sciences

AUGUST 21, 2024

Internships at Altasciences: Q&A With Our Summer Interns nbartlett Thu, 08/22/2024 - 04:44 Internships at Altasciences are more than just a stepping stone—they’re a gateway to real-world-experience and professional growth, giving the next generation opportunities to help shape progress in the drug development industry.

International 40

International Laboratories Science Molecular Biology 40

Drug Target Review

JUNE 19, 2024

From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr Culley served on the Board of Orphagen Pharmaceuticals, Inc.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

OCTOBER 25, 2024

At Johnson & Johnson, our differentiated Alzheimer’s disease research program is focused on leveraging the latest advancements in precision medicine, data science and digital health to help make earlier diagnosis an option and help treat the right patient with the right treatment at the right time. link] Cummings J. Adv Exp Med Biol.

Disease 59

Disease Clinical Trials Therapies Science 59

The Pharma Data

JANUARY 4, 2021

Barber is an associate professor of biology and director of the Office of Student Research. Dr. Barber is in her tenth year at Longwood and serves as the President-Elect of the Virginia Academy of Science. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.”

Therapies 40

Therapies Molecular Biology Immune Response Science 40

The Pharma Data

JANUARY 25, 2021

With a background in molecular biology and clinical chemistry, Dr. Zetterberg has spent the last 20 years focusing on the development of biomarkers for Alzheimer’s disease, Parkinson’s disease and other brain disorders. He is responsible for launching the professional interest area tied to immunity.

Disease 40

Disease Clinical Development Molecular Biology Treatment 40

Drug Target Review

MARCH 15, 2024

Transposon technologies are gaining traction due to their accuracy in integrating the gene of interest into the host genome, making them an important tool for accelerating large molecule drug development. Anis works within the strategy group in Life Sciences at Revvity, Inc. Disclaimer: For research use only.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

The Pharma Data

FEBRUARY 25, 2022

. “The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. 25) in the journal Communications Biology.

FDA Approval 52

FDA Approval Molecular Biology FDA Virus 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 138

Therapies Virus DNA Clinical Trials 138

Vial

MARCH 1, 2024

Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards. of total revenue).

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

BMG Labtech

MARCH 11, 2024

Enzyme-Linked Immunosorbent Assays (ELISAs) are an essential technique in today’s laboratory with many applications in the life sciences. They are often the method of choice to detect or measure specific biological molecules (analytes) for diagnostics, drug discovery or fundamental research.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

Drug Target Review

FEBRUARY 15, 2024

Advances in molecular biology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens. 2023 May 12; Available from: [link] National Academies of Sciences, Engineering, and Medicine.

Drug Development 122

Drug Development Virus Vaccine Drugs 122

Elrig

MAY 7, 2025

Held under the theme A Festival of Life Science , Drug Discovery 2025 is a celebration that aims to unite scientists from industry and academia working toward the same goal: improving human health through more effective drug discovery.

Drugs 59

Drugs Molecular Biology Science International 59

Drug Target Review

MAY 19, 2025

While many of these conditions are currently managed rather than cured, technological innovation is unlocking new possibilities for drug development. The complexity of ageing and age-related diseases requires expertise across various disciplines, from molecular biology and genetics to artificial intelligence and clinical research.

Disease 59

Disease Treatment Therapies Drug Development 59

Drug Target Review

FEBRUARY 19, 2025

His areas of expertise include biologic drug development, cell and gene therapies, and gene editing. Cedrone holds a PhD in molecular biology and enzyme engineering from Marseille University, France.

Therapies 59

Therapies Molecular Biology Regulations Packaging 59

Drug Target Review

MAY 27, 2025

Melika Davis, Senior Vice President and Global Head of Clinical Operations at BeOne , has built a career at the intersection of science and operational leadership. My masters degree in molecular biology and animal physiology provided a solid foundation for my work.

Clinical Trials 52

Clinical Trials Molecular Biology Trials Clinical Supply 52

Codon

MAY 29, 2025

While these and other peptide-based drugs weren’t patterned directly on molecules from venoms, many rely on some of the natural mechanisms by which toxins operate. A closer look at these evolutionary templates reveals why inspiration from nature’s “poisonous proteins” will continue to drive drug development.

Drugs 109

Drugs DNA RNA Laboratories 109